Abstract
Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Current Pharmaceutical Biotechnology
Title: 18F-Labeled Proteins
Volume: 11 Issue: 6
Author(s): Zhanhong Wu and Fouad Kandeel
Affiliation:
Keywords: 18F, Amine reactive prosthetic groups, Carboxylic acid reactive prosthetic groups, Thiol-reactive prosthetic groups, 18F-Labeled proteins, Positron emission tomography (PET)
Abstract: Positron emission tomography (PET) is a powerful and rapidly developing area of molecular imaging that is used to study and visualize human physiology by the detection of positron-emitting radiopharmaceuticals. Information about metabolism, receptor/enzyme function, and biochemical mechanisms in living tissue can be obtained directly from PET experiments. In particular, the interest in 18F-labeled proteins remains high for both diagnoses and therapy monitoring purposes. The development of labeling strategies for the synthesis of new 18F labeled protein is, however, not trivial. 18F-containing prosthetic groups are often required for protein labeling to obtain high yield under mild labeling conditions and keep the bioactive character of the proteins. This review highlights key aspects of protein 18F-labeling method and discussed representative examples including 18F-labeled human serum albumin, 18F-labeled Annexin V, 18F-labeled HER2 affibody, and 18F-labeled low density lipoprotein.
Export Options
About this article
Cite this article as:
Wu Zhanhong and Kandeel Fouad, 18F-Labeled Proteins, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246564
DOI https://dx.doi.org/10.2174/138920110792246564 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Innate Immunity and Intracellular Trafficking: Insights for Novel Anti- HIV-1 Therapeutics
Current Pharmacogenomics Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Peeking into the Black Box: How Cytokine Antibody Arrays Shed Light on Molecular Mechanisms of Breast Cancer Development and its Treatment
Current Proteomics Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry Hybrid Benzoxazole-Coumarin Compounds Induce Death Receptor-Mediated Switchable Apoptotic and Necroptotic Cell Death on HN-5 Head and Neck Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Recent Patents on Regenerative Medicine